Your browser doesn't support javascript.
Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant.
Mlcochova, Petra; Collier, Dami; Ritchie, Allyson; Assennato, Sonny M; Hosmillo, Myra; Goel, Neha; Meng, Bo; Chatterjee, Krishna; Mendoza, Vivien; Temperton, Nigel; Kiss, Leo; James, Leo C; Ciazynska, Katarzyna A; Xiong, Xiaoli; Briggs, John A G; Nathan, James A; Mescia, Federica; Bergamaschi, Laura; Zhang, Hongyi; Barmpounakis, Petros; Demeris, Nikos; Skells, Richard; Lyons, Paul A; Bradley, John; Baker, Steven; Allain, Jean Pierre; Smith, Kenneth G C; Bousfield, Rachel; Wilson, Michael; Sparkes, Dominic; Amoroso, Glenn; Gkrania-Klotsas, Effrosyni; Hardwick, Susie; Boyle, Adrian; Goodfellow, Ian; Gupta, Ravindra K.
  • Mlcochova P; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Collier D; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Ritchie A; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Assennato SM; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Hosmillo M; Division of Infection and Immunity, University College London, London WC1E 6BT, UK.
  • Goel N; Diagnostics for the Real World EU, Chesterford Research Park, UK.
  • Meng B; Diagnostics for the Real World EU, Chesterford Research Park, UK.
  • Chatterjee K; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Mendoza V; Diagnostics for the Real World EU, Chesterford Research Park, UK.
  • Temperton N; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Kiss L; Department of Medicine, University of Cambridge, Cambridge, UK.
  • James LC; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
  • Ciazynska KA; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
  • Xiong X; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Kent, UK.
  • Briggs JAG; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
  • Nathan JA; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
  • Mescia F; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
  • Bergamaschi L; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
  • Zhang H; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
  • Barmpounakis P; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Demeris N; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Skells R; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Lyons PA; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Bradley J; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Baker S; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Allain JP; Clinical Microbiology & Public Health Laboratory, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Smith KGC; Department of Statistics, Athens University of Economics and Business, Athens, Greece.
  • Bousfield R; Department of Statistics, Athens University of Economics and Business, Athens, Greece.
  • Wilson M; Cambridge Clinical Trials Unit-Cancer Theme, University of Cambridge, Cambridge, UK.
  • Sparkes D; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
  • Amoroso G; Cambridge Clinical Trials Unit-Cancer Theme, University of Cambridge, Cambridge, UK.
  • Gkrania-Klotsas E; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Hardwick S; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Boyle A; Division of Infection and Immunity, University College London, London WC1E 6BT, UK.
  • Goodfellow I; National Institutes for Health Research Cambridge Biomedical Research Centre, Cambridge, UK.
  • Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Cell Rep Med ; 1(6): 100099, 2020 09 22.
Article in English | MEDLINE | ID: covidwho-738567
ABSTRACT
Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild-type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI 57.8-92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Point-of-Care Testing / COVID-19 Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study Topics: Variants Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Cell Rep Med Year: 2020 Document Type: Article Affiliation country: J.xcrm.2020.100099

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Point-of-Care Testing / COVID-19 Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study Topics: Variants Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Cell Rep Med Year: 2020 Document Type: Article Affiliation country: J.xcrm.2020.100099